BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 27816721)

  • 21. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.
    Braun L; Mietzsch F; Seibold P; Schneeweiss A; Schirmacher P; Chang-Claude J; Peter Sinn H; Aulmann S
    Mod Pathol; 2013 Sep; 26(9):1161-71. PubMed ID: 23558572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and prognostic significance of ECT2 in invasive breast cancer.
    Wang HK; Liang JF; Zheng HX; Xiao H
    J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
    Bryan BB; Schnitt SJ; Collins LC
    Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
    J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
    Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
    BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
    Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
    Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
    Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of heat shock protein 10 correlates negatively with estrogen/progesterone receptor status and predicts poor prognosis in invasive ductal breast carcinoma.
    Chu S; Wen Q; Qing Z; Luo J; Wang W; Chen L; Feng J; Xu L; Zang H; Fan S
    Hum Pathol; 2017 Mar; 61():173-180. PubMed ID: 27993580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features.
    Ishikawa Y; Horiguchi J; Toya H; Nakajima H; Hayashi M; Tagaya N; Takeyoshi I; Oyama T
    Cancer Sci; 2011 Mar; 102(3):656-62. PubMed ID: 21214677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.